There has been a rise in R&D activities by leading biopharmaceutical, pharmaceutical, and biotechnology manufacturers to develop innovative antibodies such as in monoclonal antibodies. Increasing focus on R&D and development of new products is expected to propel long-term growth in the business. For instance, in 2016, Novartis invested USD 9 billion in research and development, whereas Pfizer invested USD 7.9 billion in the same year for the development of novel products and technologies. According to the International Trade Administration (ITA), U.S. Department of Commerce, the U.S. biopharmaceutical sector accounted for 17% of domestic research and development and USD 1.2 trillion in economic output in the year 2014.
Research antibodies are complex and sophisticated structures that are being increasingly used in research & academic institutions as well as major pharmaceutical & biotechnology companies, thus attracting investments in R&D for developing advanced generation of antibodies. The high prevalence of cancer and other chronic diseases has led to an increase in the demand for R&D in research antibodies. Increasing awareness among individuals about the diagnostic properties of research antibodies has led to an increase in their demand. Research antibodies such as monoclonal antibodies are being increasingly adopted globally.
Government initiatives promoting cell therapeutics research is widening market growth prospects. Due to extensive research activities, the number of diseases treated with the help of stem cells increased to 82 from 27 in 2005. CIRM’s funding of USD 271 million for stem cell research created 12 research spaces in California, which further brought in approximately USD 543 million funding for stem cell research. National Institutes of Health invested approximately USD 1,429 million for stem cell research in 2015. Increase in number of collaborations of research institutes with various public and private entities to promote cell research has provided significant boost to the market.
For instance, the federal government of Canada announced USD 20 million in funding to the Centre for Commercialization of Regenerative Medicine, a cell regeneration research facility, to improve cell therapy manufacturing challenges. Growing number of proposed guidelines and recommendations for public and private laboratories to ensure high quality standards and facilitate generation of accurate results in cell research are likely to improve adoption of cell counters in the near future. For instance, in May 2016, the International Society for Stem Cell Research (ISSCR) updated guidelines for development of cell-based therapy and stem cell research.
High growth in pharmaceutical and biopharmaceutical industries has been boosting market expansion. A major factor restraining market growth is the presence of stringent guidelines during development and research antibodies to ensure high quality products. Incorporation of cGMP and aseptic processing in all FDA regulated laboratories has made approval of research antibodies products relatively complex. In order to curb contamination, products are validated on various parameters, thereby lengthening the approval process. Stringent regulations issued by animal welfare organizations with respect to derivation process of antibodies from animal sources may also hamper market growth.
This section will provide insights into the contents included in this research antibodies market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Market drivers and restraints
Key market opportunities prioritized
Latest strategic developments
Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member